Development of a novel adenovirus purification process utilizing selective precipitation of cellular DNA

Biotechnology and Bioengineering

Volumn 91, Issue 1, 2005, Pages 12-21

  Goerke, Aaron R ^a   To, Brian C S ^a   Lee, Ann L ^a   Sagar, Sangeetha L ^a   Konz, John O ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

Adenovirus; Cationic detergents; Domiphen bromide; Host cell DNA; Precipitation

Indexed keywords

CELLS; CHROMATOGRAPHIC ANALYSIS; CONCENTRATION (PROCESS); COST EFFECTIVENESS; CYTOLOGY; DETERGENTS; PRECIPITATION (CHEMICAL); PURIFICATION; SURFACE ACTIVE AGENTS; VIRUSES;

ADENOVIRUS PURIFICATION; CATIONIC DETERGENT; DNA PRECIPITATION; NONIONIC SURFACTANT;

DNA;

ADENOVIRUS VECTOR; CELL DNA; DOMIPHEN BROMIDE; NONIONIC SURFACTANT; NUCLEASE; RESIN; SODIUM CHLORIDE;

ANION EXCHANGE CHROMATOGRAPHY; ARTICLE; CELL DENSITY; CELL LYSATE; COST EFFECTIVENESS ANALYSIS; GENE THERAPY; HUMAN; HUMAN CELL; PH; PRECIPITATION; ULTRAFILTRATION; VACCINATION; VIRUS PURIFICATION;

ADENOVIRIDAE; CHEMICAL FRACTIONATION; DNA; FRACTIONAL PRECIPITATION; ULTRAFILTRATION; VIRUS CULTIVATION;

ADENOVIRIDAE;

EID: 21344468852     PISSN: 00063592     EISSN: None     Source Type: Journal    
DOI: 10.1002/bit.20406     Document Type: Article

References (46)

1. Ahn SJ, Costa J, Emanuel JR. 1996. PicoGreen quantitation of DNA: effective evaluation of samples pre- or post-PCR. Nucleic Acids Res 24: 2623-2625.
2. Alemany R, Suzuki K, Curiel DT. 2000. Blood clearance rates of adenovirus type 5 in mice. J Gen Virol 81:2605-2609.
3. Babu GJ, Rajamanickam C. 1998. An improved method for the isolation of supercoiled plasmid DNA. Curr Sci 74:572-573.
4. Bachvarov DR, Ivanov IG. 1983. Large scale purification of plasmid DNA. Prep Biochem 13:161-166.
5. Diogo MM, Queiroz JA, Prazeres DM. 2003. Assessment of purity and quantification of plasmid DNA in process solutions using high-performance hydrophobic interaction chromatography. J Chromatogr A 998:109-117.
6. Fallaux FJ, Bout A, van der Velde I, van den Wollenberg DJ, Hehir KM, Keegan J, Auger C, Cramer SJ, van Ormondt H, van der Eb AJ, et al. 1998. New helper cells and matched early region 1-deleted adenovirus vectors prevent generation of replication-competent adenoviruses. Hum Gene Ther 9:1909-1917.
7. Gottesman MM. 2003. Cancer gene therapy: an awkward adolescence. Cancer Gene Ther 10:501-508.
8. Graham FL, Smiley J, Russell WC, Nairn R. 1977. Characteristics of a human cell line transformed by DNA from human adenovirus type 5. J Gen Virol 36:59-74.
9. Green AP, Huang JJ, Scott MO, Kierstead TD, Beaupre I, Gao GP, Wilson JM. 2002. A new scalable method for the purification of recombinant adenovirus vectors. Hum Gene Ther 13:1921-1934.
10. Gustincich S, Manfioletti G, Del Sal G, Schneider C, Carninci P. 1991. A fast method for high-quality genomic DNA extraction from whole human blood. Biotechniques 11:298-302.
11. Haruna I, Yaoi H, Kono R, Watanabe I. 1961. Separation of adenovirus by chromatography on DEAE-cellulose. Virology 13:264-267.
12. Hoopes BC, McClure WR. 1981. Studies on the selectivity of DNA precipitation by spermine. Nucleic Acids Res 9:5493-5504.
13. Huyghe BG, Liu X, Sutjipto S, Sugarman BJ, Horn MT, Shepard HM, Scandella CJ, Shabram P. 1995. Purification of a type 5 recombinant adenovirus encoding human p53 by column chromatography. Hum Gene Ther 6:1403-1416.
14. Ichikawa K, Hashizume K, Nishii Y, Takeda T, Kobayashi M, Suzuki S, Yamada T. 1991. Purification of human c-erb A beta protein. J Mol Endocrinol 7:123-129.
15. Ishaq M, Wolf B, Ritter C. 1990. Large-scale isolation of plasmid DNA using cetyltrimethylammonium bromide. Biotechniques 9:19-24.
16. Klemperer HG, Pereira HG. 1959. Study of adenovirus antigens fractionated by chromatography on DEAE-cellulose. Virology 9:536-545.
17. Lander RJ, Winters MA, Meacle FJ, Buckland BC, Lee AL. 2002. Fractional precipitation of plasmid DNA from lysate by CTAB. Biotechnol Bioeng 79:776-784.
18. Lis JT. 1980. Fractionation of DNA fragments by polyethylene glycol induced precipitation. Methods Enzymol 65:347-353.
19. Manning GS. 1978. The molecular theory of polyelectrolyte solutions with applications to the electrostatic properties of polynucleotides. Q Rev Biophys 11:179-246.
20. Mayer-Kuckuk P, Banerjee D, Kemeny N, Fong Y, Bertino JR. 2002. Molecular therapies for colorectal cancer metastatic to the liver. Mol Ther 5:492-500.
21. Merianos JJ. 2001. Surface-active agents. In: Block SS, editor. Disinfection, sterilization, and preservation, 5th ed. Philadelphia: Lippincott Williams & Wilkins. p 283-320.
22. Murakami P, McCaman MT. 1999. Quantitation of adenovirus DNA and virus particles with the PicoGreen fluorescent dye. Anal Biochem 274: 283-288.
23. Murphy JC, Wibbenmeyer JA, Fox GE, Willson RC. 1999. Purification of plasmid DNA using selective precipitation by compaction agents. Nat Biotechnol 17:822-823.
24. Nichols WW, Lardenoije R, Ledwith BJ, Brouwer K, Manam S, Vogels R, Kaslow D, Zuidgeest D, Bett AJ, Chen L, et al. 2002. Propagation of adenoviral vectors: use of PER.C6 cells. In: Curiel DT, Douglas JT, editors. Adenoviral vectors for gene therapy. New York: Academic Press, p 129-166.
25. Nicoletti VG, Condorelli DF. 1993. Optimized PEG method for rapid plasmid DNA purification: high yield from "midi-prep". Biotechniques 14:532-536.
26. Ollivier M, Stadler J. 1998. Large scale purification of plasmid DNA for use in gene therapy. In: Walden P, Trefzer U, Sterry W, Farzaneh F, editors. Gene therapy of cancer. New York: Plenum Press, p 487-492.
27. Patterson LJ, Malkevitch N, Pinczewski J, Venzon D, Lou Y, Peng B, Munch C, Leonard M, Richardson E, Aldrich K and others. 2003. Potent, persistent induction and modulation of cellular immune responses in rhesus macaques primed with Ad5hr-simian immunodeficiency virus (SIV) env/rev, gag, and/or nef vaccines and boosted with SIV gp120. J Virol 77:8607-8620.
28. Patterson LJ, Malkevitch N, Venzon D, Pinczewski J, Gomez-Roman VR, Wang L, Kalyanaraman VS, Markham PD, Robey FA, Robert-Guroff M. 2004. Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting. J Virol 78:2212-2221.
29. Philipson L. 1984. Structure and assembly of adenoviruses. Curr Top Microbiol Immunol 109:1-52.
30. Polo JM, Dubensky TW Jr. 2002. Virus-based vectors for human vaccine applications. Drug Discov Today 7:719-727.
31. Post DE, Khuri FR, Simons JW, Van Meir EG. 2003. Replicative oncolytic adenoviruses in multimodal cancer regimens. Hum Gene Ther 14:933-946.
32. Sadhu C, Gedamu L. 1988. A procedure for the preparation of RNA-free plasmid DNA. Biotechniques 6:20-21.
33. Shabram PW, Giroux DD, Goudreau AM, Gregory RJ, Horn MT, Huyghe BG, Liu XD, Nunnally MH, Sugarman BJ, Sutjipto S. 1997. Analytical anion-exchange HPLC of recombinant type-5 adenoviral particles. Hum Gene Ther 8:453-465.
34. Shabram PW, Huyghe BG, Liu X, Shepard HM; Canji, Inc., assignee. 1998. Method of purification of viral vectors. US patent 5,837,520.
35. Shenk TE. 2001. Adenoviridae: the viruses and their replication. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins. p 2265-2300.
36. Shiver JW, Emini EA. 2004. Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annu Rev Med 55:355-372.
37. Shiver JW, Fu TM, Chen L, Casimiro DR, Davies ME, Evans RK, Zhang ZQ, Simon AJ, Trigona WL, Dubey SA, et al. 2002. Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity. Nature 415:331-335.
38. Singer VL, Jones LJ, Yue ST, Haugland RP. 1997. Characterization of PicoGreen reagent and development of a fluorescence-based solution assay for double-stranded DNA quantitation. Anal Biochem 249:228-238.
39. Singhvi R, Schorr C, O'Hara C, Xie L, Wang DIC. 1996. Clarification of animal cell culture process fluids using depth filtration. BioPharm 9: 35-41.
40. Sweeney JA, Hennessey JP Jr. 2002. Evaluation of accuracy and precision of adenovirus absorptivity at 260 nm under conditions of complete DNA disruption. Virology 295:284-288.
41. Tang JC, Vellekamp G, Bondoc LL; Schering Corp., assignee. 2001. Method for purifying viruses. US patent 6,261,823 B1.
42. Xie L, Pilbrough W, Metallo C, Zhong T, Pikus L, Leung J, Aunins JG, Zhou W. 2002. Serum-free suspension cultivation of PER.C6(R) cells and recombinant adenovirus production under different pH conditions. Biotechnol Bioeng 80:569-579.
43. Xie LZ, Metallo C, Warren J, Pilbrough W, Peltier J, Zhong T, Pikus L, Yancy A, Leung J, Aunins JG, et al. 2003. Large-scale propagation of a replication-defective adenovirus vector in stirred-tank bioreactor PER.C6 (TM) cell culture under sparging conditions. Biotechnol Bioeng 83:45-52.
44. Yang ZY, Wyatt LS, Kong WP, Moodie Z, Moss B, Nabel GJ. 2003. Overcoming immunity to a viral vaccine by DNA priming before vector boosting. J Virol 77:799-803,
45. Yavorsky D, Blanck R, Lambalot C, Brunkow R. 2003. The clarification of bioreactor cell cultures for biopharmaceuticals. Pharm Technol 2003: 62-76.
46. Zhang S, Thwin C, Wu Z, Cho T; Introgen Therapeutics, assignee. 2001. Method for the production and purification of adenovirus vectors. US patent 6,194,191 B1.